{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:55:19Z","timestamp":1770998119280,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,11,25]],"date-time":"2011-11-25T00:00:00Z","timestamp":1322179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00228-011-1156-7","type":"journal-article","created":{"date-parts":[[2011,11,24]],"date-time":"2011-11-24T09:52:31Z","timestamp":1322128351000},"page":"767-775","source":"Crossref","is-referenced-by-count":32,"title":["The importance of drug\u2013drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France"],"prefix":"10.1007","volume":"68","author":[{"given":"Francois","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,25]]},"reference":[{"key":"1156_CR1","first-page":"429","volume-title":"Goodman & Gilmans\u2019 the pharmacological basis of therapeutics","author":"RJ Baldessarini","year":"2006","unstructured":"Baldessarini RJ (2006) Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 429\u2013459","edition":"11"},{"key":"1156_CR2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211\u20132221","journal-title":"N Engl J Med"},{"key":"1156_CR3","first-page":"416","volume":"31","author":"P R\u00e9daction","year":"2011","unstructured":"R\u00e9daction P (2011) Eviter les effets ind\u00e9sirables par interactions medicamenteuses: comprendre et d\u00e9cider. Rev Prescr 31:416","journal-title":"Rev Prescr"},{"key":"1156_CR4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2125.2010.03829.x","volume":"70","author":"LD Lewis","year":"2010","unstructured":"Lewis LD (2010) Drug\u2013drug interactions: is there an optimal way to study them? Br J Clin Pharmacol 70:781\u2013783","journal-title":"Br J Clin Pharmacol"},{"key":"1156_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127\u2013140","journal-title":"Fundam Clin Pharmacol"},{"key":"1156_CR6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2165\/00002018-200730110-00005","volume":"30","author":"N Tavassoli","year":"2007","unstructured":"Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montastruc JL (2007) Drug interactions with Cholinesterase inhibitors: an analysis of the French PharmacoVigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 30:1063\u20131071","journal-title":"Drug Saf"},{"key":"1156_CR7","first-page":"557","volume":"50","author":"N Moore","year":"1995","unstructured":"Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) French pharmacovigilance database system: examples of utilization. Th\u00e9rapie 50:557\u2013562","journal-title":"Th\u00e9rapie"},{"key":"1156_CR8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"1156_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"2","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory authorities. Drug Saf 2:109\u2013117","journal-title":"Drug Saf"},{"key":"1156_CR10","unstructured":"Dictionnaire (2010) VIDAL, 86th edn. OVP, Paris"},{"key":"1156_CR11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00002826-200305000-00007","volume":"26","author":"M Gony","year":"2003","unstructured":"Gony M, Lapeyre-Mestre M, Montastruc JL (2003) Risk of serious extrapyramidal symptoms in patients with Parkinson\u2019s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 26:142\u2013145","journal-title":"Clin Neuropharmacol"},{"key":"1156_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00228-005-0080-0","volume":"62","author":"E Guitton","year":"2006","unstructured":"Guitton E, Montastruc JL (2006) Lapeyre-Mestre M and the French Network of PharmacoVigilance Centers: influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 62:243\u2013249","journal-title":"Eur J Clin Pharmacol"},{"key":"1156_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2515\/therapie:2007076","volume":"62","author":"S Berthet","year":"2007","unstructured":"Berthet S, Grolleau S, Brefel-Courbon C, Montastruc JL, Lapeyre-Mestre M (2007) Prevalence of diabetes in France and drug use: study based on the French PharmacoVigilance database. Th\u00e9rapie 62:483\u2013488","journal-title":"Th\u00e9rapie"},{"key":"1156_CR14","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1038\/clpt.2010.213","volume":"88","author":"CV Fletcher","year":"2010","unstructured":"Fletcher CV (2010) Drug interactions should be evaluated in patients. Clin Pharmacol Ther 88:5857","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"1156_CR15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003088-199500291-00004","volume":"29","author":"L Ereshefsky","year":"1995","unstructured":"Ereshefsky L, Riesenman C, Lam YW (1995) Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 29[Suppl 1]:10\u201318","journal-title":"Clin Pharmacokinet"},{"key":"1156_CR16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","volume":"33","author":"BA Sproule","year":"1997","unstructured":"Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 33:454\u2013471","journal-title":"Clin Pharmacokinet"},{"key":"1156_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00002512-200219040-00004","volume":"19","author":"E Spina","year":"2002","unstructured":"Spina E, Scordo MG (2002) Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19:299\u2013320","journal-title":"Drugs Aging"},{"key":"1156_CR18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206\u20131227","journal-title":"Clin Ther"},{"key":"1156_CR19","first-page":"395","volume":"55","author":"N Remy","year":"2000","unstructured":"Remy N, Lapeyre-Mestre M, Bareille MP, Bagheri H, Montastruc JL (2000) Drug interactions: a prospective study in primary health care. Th\u00e9rapie 55:395\u2013398","journal-title":"Th\u00e9rapie"},{"key":"1156_CR20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2125.1998.00667.x","volume":"45","author":"N Moore","year":"1998","unstructured":"Moore N, Le Cointre D, Noblet C, Mabille M (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45:301\u2013308","journal-title":"Br J Clin Pharmacol"},{"key":"1156_CR21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMsa020703","volume":"348","author":"TK Ghandi","year":"2003","unstructured":"Ghandi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556\u20131564","journal-title":"N Engl J Med"},{"key":"1156_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-199920030-00007","volume":"20","author":"O Spigset","year":"1999","unstructured":"Spigset O (1999) Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20:277\u2013287","journal-title":"Drug Saf"},{"key":"1156_CR23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0953-6205(01)00159-5","volume":"12","author":"JB Wasserfallen","year":"2001","unstructured":"Wasserfallen JB, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J (2001) Rate, type and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 12:442\u2013447","journal-title":"Eur J Intern Med"},{"key":"1156_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scot AK, Walley TL, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329:15\u201319","journal-title":"Br Med J"},{"key":"1156_CR25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2165\/11534400-000000000-00000","volume":"33","author":"R Leone","year":"2010","unstructured":"Leone R, Magro L, Moreti L, Cutrneo P, Moschini M, Motola D, Tuccori M, Conforti A (2010) Identifying adverse drug reactions associated with drug-drug interactions. Drug Saf 33:667\u2013675","journal-title":"Drug Saf"},{"key":"1156_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002280100263","volume":"57","author":"D Layton","year":"2001","unstructured":"Layton D, Clark DW, Pearce GL, Shakir SA (2001) Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleedings? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 57:167\u2013176","journal-title":"Eur J Clin Pharmacol"},{"key":"1156_CR27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00023210-200620020-00005","volume":"20","author":"SO Dalton","year":"2006","unstructured":"Dalton SO, Sorensen HT, Johansen C (2006) SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 20:143\u2013151","journal-title":"CNS Drugs"},{"key":"1156_CR28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.2010.03797.x","volume":"71","author":"I Douglas","year":"2011","unstructured":"Douglas I, Smeeth L, Irvine D (2011) The use of antidepressants and the risk of stroke: a nested case control study. Br J Clin Pharmacol 71:116\u2013120","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1156-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1156-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1156-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:48:55Z","timestamp":1558702135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1156-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,25]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1156-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,25]]}}}